Researcher.Life Logo

Melanoma Research : Impact Factor & More

eISSN: 1473-5636pISSN: 0960-8931

Aims and Scope of Melanoma Research

Melanoma Research (print: ISSN 0960-8931, online: ISSN 1473-5636) is a peer-reviewed medical journal published by Lippincott Williams & Wilkins since 1991. The journal publishes current findings on melanoma. Articles include both experimental and clinical research in a broad range of related subjects, including genetics, molecular biology, biochemistry, cell biology, photobiology, pathology, and immunology, and advances in clinical oncology influencing the prevention, diagnosis, and treatment of melanoma. Melanoma Research is published bimonthly. The current editor-in-chief is F.J. Lejeune. Less

Key Metrics

CiteScore
6.7
Eigenfactor
0.001 - 0.005
Impact Factor
< 5
SJR
Q2Oncology
SNIP
0.88
Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on Melanoma Research

Melanoma Research Journal Specifications

Overview
Publisher LIPPINCOTT WILLIAMS & WILKINS
Language English
Frequency Bi-monthly
General Details
LanguageEnglish
FrequencyBi-monthly
Publication Start Year1991
Publisher URLVisit website
Website URLVisit website
View less

Planning to publish in Melanoma Research ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in Melanoma Research

Variability in synoptic reporting and inclusion of essential histopathologic elements in cutaneous melanoma biopsy pathology reports.
  • 14 May 2026
  • Melanoma research
Re-evaluating melanoma treatment: a comparative look at herpes simplex virus and coxsackievirus oncolytic therapies in advanced melanoma: a meta-analysis of clinical trials.
  • 14 May 2026
  • Melanoma research
Sentinel lymph node detection in melanoma: indocyanine green fluorescence compared with conventional mapping techniques.
  • 11 May 2026
  • Melanoma research
Novel uveal melanoma patient-derived cell line and organoid models show increased treatment resistance compared with commercially available cell lines.
  • 11 May 2026
  • Melanoma research
High dose interleukin-2 in combination with anti-programmed cell death protein 1 to overcome immune checkpoint inhibitor resistance in metastatic melanoma and renal cell carcinoma.
  • 30 Apr 2026
  • Melanoma research
E26 transformation-specific translocation variant 4 participates in melanoma progression and immune evasion by mediating the CD47molecule/signal regulatory protein α pathway.
  • 27 Apr 2026
  • Melanoma research
Variability in synoptic reporting and inclusion of essential histopathologic elements in cutaneous melanoma biopsy pathology reports.
  • 14 May 2026
  • Melanoma research
Re-evaluating melanoma treatment: a comparative look at herpes simplex virus and coxsackievirus oncolytic therapies in advanced melanoma: a meta-analysis of clinical trials.
  • 14 May 2026
  • Melanoma research
Sentinel lymph node detection in melanoma: indocyanine green fluorescence compared with conventional mapping techniques.
  • 11 May 2026
  • Melanoma research
Novel uveal melanoma patient-derived cell line and organoid models show increased treatment resistance compared with commercially available cell lines.
  • 11 May 2026
  • Melanoma research
High dose interleukin-2 in combination with anti-programmed cell death protein 1 to overcome immune checkpoint inhibitor resistance in metastatic melanoma and renal cell carcinoma.
  • 30 Apr 2026
  • Melanoma research
E26 transformation-specific translocation variant 4 participates in melanoma progression and immune evasion by mediating the CD47molecule/signal regulatory protein α pathway.
  • 27 Apr 2026
  • Melanoma research

FAQs on Melanoma Research